MSLN and ovarian carcinoma: However, heterogeneous intratumoural MSLN expression (up to 25% of tumor cells without MSLN expression, data not shown) was observed in this study, and our group is trying to identify compounds that are more efficient in MSLN negative/positive ovarian cancer cells, that might be valuable to use in combination with MSLN targeted therapies.